25 |
Japanese Experience with Zilver PTX |
Hiroyoshi Yokoi |
Apr. 20. 15 |
24 |
Zilver PTX 5-year Data: What Does It Mean to Clinical Practice? |
Mark W. Burket |
Apr. 20. 15 |
23 |
Nitinol Self-Expanding Stents Works Still! |
Lawrence A. Garcia |
Apr. 20. 15 |
22 |
Atherectomy Should Be Used in All SFA Disease |
Ravish Sachar |
Apr. 20. 15 |
21 |
5-Year Results of Zilver PTX Randomized Trial: DES Is Default |
Hiroyoshi Yokoi |
Apr. 20. 15 |
20 |
IN PACT SFA Randomized Trial: DCB Becomes First Line Therapy |
Seung-Whan Lee |
Apr. 20. 15 |
19 |
Novel Wiring Tips for SFA-CTO |
Kazushi Urasawa |
Apr. 20. 15 |
18 |
DCB Will Become Dominant Therapy, with DES Reserved for Bail-out! |
Antonio Micari |
May. 09. 14 |
17 |
[Great Debate] Con: No More Device, Lack of Evidence |
Lawrence A. Garcia |
May. 09. 14 |
16 |
[Great Debate] Pro: Stenting with/without Drug-eluting Technology Is Essential to Treat the SFA Disease. |
John R. Laird |
May. 09. 14 |